IDRX-42 is named as an intervention in 2 current clinical trials in our UK, USA and China registers. 1 is recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is IDRX, Inc., a wholly owned subsidiary of GSK, LLC (1). The most-studied condition is Gastrointestinal Neoplasms.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
NCT07218926 · ClinicalTrials.gov ↗ · Gastrointestinal Neoplasms
|
Phase 3 | Recruiting | GlaxoSmithKline | UK, USA, China |
|
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
NCT05489237 · ClinicalTrials.gov ↗ · Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease
|
Phase 1 | Active, closed | IDRX, Inc., a wholly owned subsidiary of GSK, LLC | UK, USA, China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| IDRX, Inc., a wholly owned subsidiary of GSK, LLC | 1 |
| GlaxoSmithKline | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in UK | 2 | 1 |
| Clinical trials in USA | 2 | 1 |
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our UK, USA and China registers name IDRX-42 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in UK, 1 with sites in USA and 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
IDRX, Inc., a wholly owned subsidiary of GSK, LLC (1) and GlaxoSmithKline (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how IDRX-42 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how IDRX-42 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists IDRX-42 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.